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audit compared with expected population numbers – perhaps, 
at least in part, reflecting differing workload and staffing issues 
and level of support from clinical audit departments. There was 
considerable variation in the proportion of patients being seen 
within this timeframe, ranging from 55% in London to 28–39% 
elsewhere in the UK. The number of consultants per 100,000 of 
the population and the presence of an EIA clinic were the major 
identifiable factors associated with this. Anecdotally, the audit 
data is already being used to support arguments for additional 
support and the development of EIA clinics. A second iteration 
of the audit is planned for 2017–8 and it will be important to 
see whether, like other national clinical audits, it has driven 
measurable change in practice. All the indications so far are 
that it will and that it will also highlight the need to support 
and properly resource those units who are struggling to achieve 
the audit standards so as to give all patients with EIA the same 
high-quality care, wherever they live. ■ 
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 In the early 2000s, clinical research in the UK was at a low 
ebb; most universities prioritised basic biomedical research, 
training opportunities were limited and clinician-researchers 
were declining in number and felt disenfranchised. An 
Academy of Medical Sciences report 1 identified ‘a substantial 
gulf between basic discoveries and converting such discoveries 
into innovations that directly benefit patients or prevent 
disease’. Government sponsored reports 2 identified the 
possibility of using the NHS as a testbed for interventions 
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that would improve its efficiency and effectiveness while 
also promoting the UK life sciences industry. On paper, the 
Department of Health had a substantial budget for research 
and development but, in practice, most of this was historically 
tied into the bricks and mortar of major teaching hospitals, 
with little accountability for research outputs. The need for a 
relaunch of NHS-based clinical research was clear. 
 The result was a new government policy in 2006, 3 which 
set out the vision for a new National Institute for Health 
Research (NIHR), established in April that year, to ‘create a 
health research system in which the NHS supports outstanding 
individuals, working in world-class facilities, conducting 
leading-edge research, focused on the needs of patients and 
the public’ and a mandate to be radical in how it achieved 
that. This ambitious strategy was widely, but not universally, 
supported. The Cooksey review supported the NIHR and 
defined complementary roles for the two major public 
funders – the NIHR with clinical and applied research and the 
Medical Research Council biomedical and discovery science. 
Clinical Medicine 2016 Vol 16, No 6: 501–2 EDITORIALS
CMJv16n6-Bowman.indd   501 15/11/16   8:47 PM
502 © Royal College of Physicians 2016. All rights reserved.
The treasury gave an enhanced budget and money previously 
locked into NHS organisations was freed up over 3 years for 
reinvestment, in line with the national strategy. 
 Ten years on, 4 the NIHR is the largest national clinical 
research funder in Europe. Major work areas include its own 
research programmes, NHS research, infrastructure support, 
research training and systems to underpin the clinical research 
environment more widely. 
 The NIHR now funds over £1 billion of research each year, 
including around 750 randomised controlled trials at a time. The 
topics have all been identified as major priorities for the NHS, 
public health or social care and even with the multi-year lead 
time between research being initiated and policy change, many of 
these studies have already changed clinical practice and improved 
outcomes for patients. One example of many 5 is the CRASH-2 
study, 6 which showed that an off-patent drug, tranexamic acid, 
can reduce mortality after trauma; initially adopted by the army, 
and later by UK ambulance services and accident and emergency 
departments, it is now used in routine practice. The NIHR also 
promotes best practice in the conduct of studies, supporting the 
research design service and clinical trials units, and ensures high 
rates of publication of results and access to data. 7,8 
 Infrastructure includes biomedical research centres, which 
have proved to be powerhouses for translational research, 
cementing links between academic institutes and the NHS 
for mutual benefit. The Clinical Research Network provides 
infrastructure to support research funded by the NIHR and 
research funded by partners – including charities, industry and 
other government funders. This has significantly improved 
patient access to research; all NHS trusts in England now 
support opportunities for patients to participate in clinical 
research, with 42% of general practices research-active. 
Evidence is emerging 9 of the wider beneficial impact on clinical 
services of research-active NHS organisations. Collaborations 
for Leadership in Applied Health Research and Care work at the 
interface between research and practice. 
 Developing the next generation of research leaders in clinical 
research is essential to the UK. The NIHR has helped to stem 
the decline in clinical research capacity, offering support at 
critical points in the career pathway for medical and other 
trainees; its importance was recently highlighted by the 
Royal College of Physicians. 10 The NIHR has a programme 
of highly competitive training awards for medical and non-
medical professions. As part of the Integrated Academic 
Training Programme, pre-doctoral NIHR academic clinical 
fellowships (over 2,200 awarded since 2006) provide a vital 
introduction to research for clinicians during their specialty 
training. Additional trainees are supported via programme and 
infrastructure funding. The long-term financial commitment 
necessary to develop and maintain the next generation of 
research leaders in applied health research is there. 
 The NIHR has been built on solid foundations of excellence 
in both science and clinical practice across universities 
and the NHS, and given opportunities to clinicians to 
 re-engage with research; it has attracted support from all 
of these constituencies; it has been promoted by successive 
governments, reaffirming their belief in the reciprocal link 
between better evidence, health and economic growth, as best 
exemplified by the life sciences sector. 
 There are two other groups without whose support, the 
NIHR could not succeed: industry, which has responded to 
the manifest improvements made by the NIHR in the NHS 
environment for research, bringing more trials and research to 
the UK and, most important of all, patients and the public. The 
NIHR has always stressed, as a core value, the importance of 
patient and public involvement and engagement at every step 
in the research process – from the setting of priorities through 
to the delivery, dissemination and implementation of results. 
 How will the NIHR fare in the future? The NIHR has thrived 
by collaboration with partners driven by the same aims; by 
promoting science of the highest quality; and by keeping its 
focus on the future needs of the NHS and the nation. There 
are clear challenges and opportunities ahead. Public health 
needs and responding to changing demographics will drive 
NIHR programmes. New areas of science, including the digital 
revolution and precision medicine technologies, have the 
potential to transform the nature of large areas of healthcare. 
The changing organisation of health services, public health and 
social care needs to be informed by solid evidence and subject 
to robust evaluation. The NIHR and clinical and applied 
research have travelled a long way in the past 10 years. The 
need for a world-class research system to ensure the NHS and 
public health and social care systems achieve the goal of clinical 
and care excellence is evident and, despite the well-recognised 
challenges, the progress of the NIHR over the past decade 
augurs well for the future of healthcare. And of course, as we 
consider a post-Brexit world, the NIHR will be at the core of the 
new industrial strategy. ■ 
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